Background: CD4 +Foxp3 + regulatory T cells (Treg) inhibit T-cell proliferation in vitro and are effective in suppressing colitis in mouse models. Tumor necrosis factor (TNF)-?, which is centrally involved in Crohns disease (CD) pathogenesis, also impairs Treg function. Here we investigated the influence of anti-TNF therapy on Treg frequency and function in CD. Methods: Twenty CD patients were treated with infliximab administered at weeks 0, 2, and 6. Blood was collected immediately before the first infusion and after 10 weeks. Treg frequency was quantified by flow cytometry. Treg function was measured using a standard coculture assay. Serum levels of transforming growth factor (TGF)-β1 and interleukin (IL)-10 were measured by enzyme-linked immunosorbent assay (ELISA). Results: Pretreatment Treg frequency and serum TGF-β1 levels were significantly higher in nonresponder than responder patients. Clinical improvement in 12 CD patients was associated with a significant increase of Treg frequency after 10 weeks. Treg were functionally active before and after treatment with infliximab, both in responder and nonresponder CD patients. In responder patients the restoration of Treg pool was accompanied by a parallel significant increase of serum TGF-β1 and IL-10. No significant change in the elevated Treg or serum TGF-β1 was seen in nonresponder patients. Conclusions: This study suggests that there may be a relationship between numbers of Treg in the blood, serum TGF-β1, and response to infliximab; however, further prospective studies are needed. (Inflamm Bowel Dis 2010) © 2010 Crohns & Crohns & Colitis Foundation of America, Inc.

Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohns disease / Antonio Di, Sabatino; Paolo, Biancheri; Piconese, Silvia; Manuela M., Rosado; Sandro, Ardizzone; Laura, Rovedatti; Cristina, Ubezio; Alessandro, Massari; Gianluca M., Sampietro; Diego, Foschi; Gabriele Bianchi, Porro; Mario P., Colombo; Rita, Carsetti; Thomas T., Macdonald; Gino R., Corazza. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 16:11(2010), pp. 1891-1897. [10.1002/ibd.21271]

Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohns disease

PICONESE, SILVIA;
2010

Abstract

Background: CD4 +Foxp3 + regulatory T cells (Treg) inhibit T-cell proliferation in vitro and are effective in suppressing colitis in mouse models. Tumor necrosis factor (TNF)-?, which is centrally involved in Crohns disease (CD) pathogenesis, also impairs Treg function. Here we investigated the influence of anti-TNF therapy on Treg frequency and function in CD. Methods: Twenty CD patients were treated with infliximab administered at weeks 0, 2, and 6. Blood was collected immediately before the first infusion and after 10 weeks. Treg frequency was quantified by flow cytometry. Treg function was measured using a standard coculture assay. Serum levels of transforming growth factor (TGF)-β1 and interleukin (IL)-10 were measured by enzyme-linked immunosorbent assay (ELISA). Results: Pretreatment Treg frequency and serum TGF-β1 levels were significantly higher in nonresponder than responder patients. Clinical improvement in 12 CD patients was associated with a significant increase of Treg frequency after 10 weeks. Treg were functionally active before and after treatment with infliximab, both in responder and nonresponder CD patients. In responder patients the restoration of Treg pool was accompanied by a parallel significant increase of serum TGF-β1 and IL-10. No significant change in the elevated Treg or serum TGF-β1 was seen in nonresponder patients. Conclusions: This study suggests that there may be a relationship between numbers of Treg in the blood, serum TGF-β1, and response to infliximab; however, further prospective studies are needed. (Inflamm Bowel Dis 2010) © 2010 Crohns & Crohns & Colitis Foundation of America, Inc.
2010
foxp3; il-10; suppression assay; tnf-?
01 Pubblicazione su rivista::01a Articolo in rivista
Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohns disease / Antonio Di, Sabatino; Paolo, Biancheri; Piconese, Silvia; Manuela M., Rosado; Sandro, Ardizzone; Laura, Rovedatti; Cristina, Ubezio; Alessandro, Massari; Gianluca M., Sampietro; Diego, Foschi; Gabriele Bianchi, Porro; Mario P., Colombo; Rita, Carsetti; Thomas T., Macdonald; Gino R., Corazza. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 16:11(2010), pp. 1891-1897. [10.1002/ibd.21271]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/382311
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 37
social impact